Since the introduction of second-generation antipsychotics (SGAs), their prescription has increased significantly in women with mental health disorders, and a growing number of pregnant women are being exposed to them. However, the available information regarding the safety of these drugs in pregnant women is still limited, and an individualized assessment is necessary for each woman and each case.